LBRXLB Pharmaceuticals Inc Common StockHealthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $42.57 · now $42.57 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, LBRX has typically landed between $37.29 and $59.59 — a range of −12.4% to +40.0% from the issuance price $42.57.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

234 overlapping 1 month windows · 2025-09-112026-08-17 · basis climatology · forecast (batch).

The cone is anchored at the 2026-09-16 issuance close ($42.57) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where LBRX has typically landed a month from the 2026-09-16 close of $42.57 — the range is history, not a prediction.

$37.29worst · -12.4%$59.59best · +40.0%
  • now $42.57 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $46.27 (+8.7%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $41.96$50.58
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $37.29$59.59
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 234 windows spanning 2025-09-11 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2026-05-01−14.0%−14.0%+4.6%
2026-04-20−13.9%−13.9%+3.8%
2026-05-11−13.2%−17.4%+0.0%
3 best
2026-07-20+57.8%+0.0%+57.8%
2026-07-16+56.2%+0.0%+57.5%
2026-07-21+51.5%+0.0%+51.5%

234 overlapping windows · 2025-09-112026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~1 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
0%
−3.6%
n=1
Feb
100%
+11.9%
n=1
Mar
100%
+2.7%
n=1
Apr
100%
+28.6%
n=1
May
0%
−11.8%
n=1
Jun
100%
+16.1%
n=1
Jul
100%
+23.5%
n=1
Aug
100%
+17.9%
n=1
Sep
0%
−9.9%
n=1
Oct
100%
+2.2%
n=1
Nov
100%
+10.3%
n=1
Dec
100%
+25.1%
n=1

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$49$152026-07-30: 1 insider purchase, $10.0M — Deep Track Biotechnology Master Fund, Ltd.2026-02-06: 2 insider purchases, $10.0M — Deep Track Biotechnology Master Fund, Ltd. …2025-09-12: 6 insider purchases, $75.0M — Deep Track Biotechnology Master Fund, Ltd., Pontifax Management 4 G.P. (2015) Ltd., Nussbaum Ran, Vida Ventures GP III, L.L.C. …2025-09: 6 open-market purchases, $75.0M2026-02: 2 open-market purchases, $10.0M2026-07: 1 open-market purchase, $10.0M↑ buys↓ salestenPercentOwner Deep Track Biotechnology Master Fund, Ltd. — Purchase on 2026-07-30, filed 4 days after the tradetenPercentOwner Deep Track Biotechnology Master Fund, Ltd. — Purchase on 2026-02-06, filed 4 days after the tradetenPercentOwner Deep Track Biotechnology Master Fund, Ltd. — Purchase on 2026-02-06, filed 4 days after the tradetenPercentOwner Deep Track Biotechnology Master Fund, Ltd. — Purchase on 2025-09-12, filed 4 days after the tradetenPercentOwner Pontifax Management 4 G.P. (2015) Ltd. — Purchase on 2025-09-12, filed 4 days after the tradedirector Nussbaum Ran — Purchase on 2025-09-12, filed 4 days after the tradetenPercentOwner Deep Track Biotechnology Master Fund, Ltd. — Purchase on 2025-09-12, filed 4 days after the tradetenPercentOwner Vida Ventures GP III, L.L.C. — Purchase on 2025-09-12, filed 4 days after the tradetenPercentOwner Vida Ventures GP III, L.L.C. — Purchase on 2025-09-12, filed 4 days after the trade
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2026-07-30Deep Track Biotechnology Master Fund, Ltd.tenPercentOwnerPurchase286,205 @ $34.94$10.0M+75.6% of holding+13.0%not yet — horizon still open664,649Form 4 · filed 4 days after the trade
2026-02-06Deep Track Biotechnology Master Fund, Ltd.tenPercentOwnerPurchase378,444 @ $21.17$8.0Mownership Δ n/a+2.8%+80.0%378,444Form 4 · filed 4 days after the trade
2026-02-06Deep Track Biotechnology Master Fund, Ltd.tenPercentOwnerPurchase93,925 @ $21.17$2.0Mownership Δ n/a+2.8%+80.0%93,925Form 4 · filed 4 days after the trade
2025-09-12Deep Track Biotechnology Master Fund, Ltd.tenPercentOwnerPurchase2,000,000 @ $15.00$30.0M+291.5% of holding−5.5%+55.1%2,686,138Form 4 · filed 4 days after the trade
2025-09-12Pontifax Management 4 G.P. (2015) Ltd.tenPercentOwnerPurchase1,000,000 @ $15.00$15.0M+242.9% of holding−5.5%+55.1%1,411,681Form 4 · filed 4 days after the trade
2025-09-12Nussbaum RandirectorPurchase1,000,000 @ $15.00$15.0M+242.9% of holding−5.5%+55.1%1,411,681Form 4 · filed 4 days after the trade
2025-09-12Deep Track Biotechnology Master Fund, Ltd.tenPercentOwnerPurchase666,666 @ $15.00$10.0Mownership Δ n/a−5.5%+55.1%666,666Form 4 · filed 4 days after the trade
2025-09-12Vida Ventures GP III, L.L.C.tenPercentOwnerPurchase332,566 @ $15.00$5.0M+60.7% of holding−5.5%+55.1%880,214Form 4 · filed 4 days after the trade
2025-09-12Vida Ventures GP III, L.L.C.tenPercentOwnerPurchase767 @ $15.00$12K+60.8% of holding−5.5%+55.1%2,029Form 4 · filed 4 days after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

125 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-06-03Lenz Robert A.directorAward / grant12,50012,500Form 4
2026-06-03Nussbaum RandirectorAward / grant10,00010,000Form 4
2026-06-03Garland J. ScottdirectorAward / grant10,00010,000Form 4
2026-06-03RUFFOLO ROBERT RdirectorAward / grant10,00010,000Form 4
2026-06-03Hemrajani RekhadirectorAward / grant10,00010,000Form 4
2026-06-03Kane William P JrdirectorAward / grant10,00010,000Form 4
2026-06-03Luse RebeccadirectorAward / grant10,00010,000Form 4
2026-03-06Lenz Robert A.directorAward / grant20,00020,000Form 4
2025-12-10Pai Panandiker Kaya KamleshofficerAward / grant195,000195,000Form 4
2025-09-12Vida Ventures GP III, L.L.C.tenPercentOwnerConversion13,302,6660Form 4
2025-09-12Vida Ventures GP III, L.L.C.tenPercentOwnerConversion30,6670Form 4
2025-09-12Deep Track Biotechnology Master Fund, Ltd.tenPercentOwnerConversion16,666,6670Form 4
2025-09-12Pontifax Management 4 G.P. (2015) Ltd.tenPercentOwnerConversion10,000,0000Form 4
2025-09-12Pontifax Management 4 G.P. (2015) Ltd.tenPercentOwnerConversion411,681411,681Form 4
2025-09-12Nussbaum RandirectorConversion10,000,0000Form 4
2025-09-12Nussbaum RandirectorConversion411,681411,681Form 4
2025-09-12Vida Ventures GP III, L.L.C.tenPercentOwnerConversion1,2621,262Form 4
2025-09-12Deep Track Biotechnology Master Fund, Ltd.tenPercentOwnerConversion686,138686,138Form 4
2025-09-12Vida Ventures GP III, L.L.C.tenPercentOwnerConversion547,648547,648Form 4
2025-09-12Pontifax Management 4 G.P. (2015) Ltd.tenPercentOwnerConversion411,681411,681Form 4
2025-09-12Vida Ventures GP III, L.L.C.tenPercentOwnerConversion1,2621,262Form 4
2025-09-12Vida Ventures GP III, L.L.C.tenPercentOwnerConversion547,648547,648Form 4
2025-09-12Deep Track Biotechnology Master Fund, Ltd.tenPercentOwnerConversion16,666,6670Form 4
2025-09-12Deep Track Biotechnology Master Fund, Ltd.tenPercentOwnerConversion686,138686,138Form 4
2025-09-12Deep Track Biotechnology Master Fund, Ltd.tenPercentOwnerConversion16,666,6670Form 4
2025-09-12Deep Track Biotechnology Master Fund, Ltd.tenPercentOwnerConversion686,138686,138Form 4
2025-09-12Deep Track Biotechnology Master Fund, Ltd.tenPercentOwnerConversion16,666,6670Form 4
2025-09-12Deep Track Biotechnology Master Fund, Ltd.tenPercentOwnerConversion686,138686,138Form 4
2025-09-12Vida Ventures GP III, L.L.C.tenPercentOwnerConversion1,2621,262Form 4
2025-09-12Vida Ventures GP III, L.L.C.tenPercentOwnerConversion547,648547,648Form 4
2025-09-12Vida Ventures GP III, L.L.C.tenPercentOwnerConversion1,2621,262Form 4
2025-09-12Vida Ventures GP III, L.L.C.tenPercentOwnerConversion547,648547,648Form 4
2025-09-12Vida Ventures GP III, L.L.C.tenPercentOwnerConversion1,2621,262Form 4
2025-09-12Vida Ventures GP III, L.L.C.tenPercentOwnerConversion547,648547,648Form 4
2025-09-12Vida Ventures GP III, L.L.C.tenPercentOwnerConversion547,648547,648Form 4
2025-09-12Vida Ventures GP III, L.L.C.tenPercentOwnerConversion1,2621,262Form 4
2025-09-12Pontifax Management 4 G.P. (2015) Ltd.tenPercentOwnerConversion10,000,0000Form 4
2025-09-12Nussbaum RandirectorConversion10,000,0000Form 4
2025-09-12Nussbaum RandirectorConversion411,681411,681Form 4
2025-09-10Turner Heather DdirectorAward / grant971,828971,828Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.